针对糖尿病患者的医疗设备制造商德康医疗公司(DXCM)今日盘中大涨5.04%。消息人士透露,此前知名投行Baird上调了德康医疗的评级和目标股价,或是其股价大涨的主要推手。
分析人士称,Baird上调了对德康医疗的评级,由中性上调至优于大市评级,并将该公司的目标价从86美元上调至104美元。市场认为,这体现了分析师对德康医疗未来表现的乐观预期及较高估值认可。
德康医疗主攻连续血糖监测系统,期望改变糖尿病传统血糖检测工艺,并与胰岛素泵集成实现胰岛素的自动输送。受益于糖尿病患病人群扩大,该公司长期发展前景备受看好。因此投行给予较高评级和目标价调整的利好消息,促使投资者加码布局德康医疗股票,股价应声大涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.